Cambridge Healthtech Institute’s 11th Annual
Driving Clinical Success in Antibody-Drug Conjugates
Lessons Learned and New Engineering Approaches for Next-Wave ADCs
May 12-13, 2021
In the past year, antibody-drug conjugates have seen exponential approval growth, indicating an optimistic future for these targeted therapies. This is testimonial to the increased understanding of the mechanisms and design of ADCs, particularly in pairing
the right antibodies with the right toxic agents. This has given rise to an ADC boom, with over 70 ADCs in active clinical trials and dozens more in preclinical development.
CHI’s Driving Clinical Success in Antibody-Drug Conjugates conference will look at the critical success factors of these approved ADCs and rising stars, as well as explore where companies are bringing their ADCs next – from using ADCs to target
the tumor microenvironment to IO combinations to enhance ADCs; from Fc engineering to designing immuno-competent mouse models; and show how these strategies may drive the next wave of ADC clinical success.
Coverage will include, but is not limited to:
- Clinical Lessons Learned:
- What are the drivers of clinical success of approved ADCs? What do they have in common?
- Targets – why go after the same targets? Eg: HER2, TROP2 – what sets these ADCs apart?
- Rising Stars and Upcoming Approvals
- Clinical and Preclinical updates
- ADCs Targeting the Tumor Microenvironment
- Delivering agonist to activate T cells, macrophages and the immune system
- Targeting stromal cells, endothelial cells
- Increase knowledge of tumor biology
- Driving immune response and interaction with immune system
- STING agonists
- Using ADCs to overcome immunosuppression of tumors
- Using immunotherapy to enhance ADCs
- Fc Engineering for Next-Wave of ADCs
- Agonist as Payloads, or Combination of ADC with Agonists
- Mechanistic Insights of ADCs – new payloads, new mechanisms, new chemistry
- Translational research – biomarkers and immuno-competent mouse models
If you would like to submit a proposal to give a presentation at this meeting, please click here.
The deadline for priority consideration is November 6, 2020.
All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.
For more details on the conference, please contact: Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
For partnering and sponsorship information, please contact:
Senior Manager, Business Development
Manager, Business Development